Ribozyme Pharmaceuticals, Incorporated

Isis Pharmaceuticals, Inc.

Other

Kenneth G Draper

James A McSwiggen

Dan T Stinchcomb

James D Thompson

Sean M Sullivan

David J Ecker

Stanley T Crooke

Christopher K Mirabelli

Kevin P Anderson

Susan Grimm

Bharat Chowrira

Daniel L Kisner

Thale Jarvis

Pamela Pavco

John Gustofson

Sharon K Chapman

Jacqueline R Wyatt

Brenda F Baker

Ronnie C Hanecak

Vickie L Brown-Driver

Dennis G Macejak

Pam Pavco

Tod Woolf

Kevin Kisich

Sharon Chapman

An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of Burkitt's lymphoma or acute lymphocytic leukemia.

Method and reagent for treatment of diseases by expression of the c-Myc gene

An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of lung cancer.

Method and reagent for treatment of lung cancer and other malignancies caused by the deregulation of L-MYC gene expression

An enzymatic RNA molecule which specifically cleaves a herpes simplex virus mRNA molecule.

Method and reagent for inhibiting herpes simplex virus replication

The present invention relates to enzymatic RNA molecules which cleave ICAM-1 mRNA.

Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (CAM-1)

Enzymatic RNA molecules which cleave rel A mRNA.

Ribozyme treatment of diseases or conditions related to levels of NF-&kgr;B

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

Oligonucleotide therapies for modulating the effects of herpesviruses

An enzymatic RNA molecule which specifically cleaves an influenza virus RNA.

Method and reagent for inhibiting influenza virus replication

An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.

Method and reagent for inhibiting human immunodeficiency virus

This invention concerns compositions and methods for the treatment of CMV infections. Antisense oligonucleotides are provided which are effective antiviral agents. In preferred embodiments, the oligonucleotides contain at least one 2'-methoxyethoxy modification and may be chimeric oligonucleotides.

Composition and method for treatment of CMV infections

An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis C virus.

Method and reagent for inhibiting hepatitis C virus replication

Enzymatic RNA molecules which cleave ICAM-1 mRNA.

Ribozyme treatment of diseases or conditions related to levels of

An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis B virus.

Growing community of inventors

Boulder, CO, United States of America

Kenneth G Draper